|
Open-Label study of ASP9801, an Oncolytic Virus administered by intratumoral injection in patients with advanced/metastatic solid tumors (9801-CL-0101) |
I |
|
|
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 with Gemzar and Oxaliplatin for the Treatment of Subjects with RElapsed or Refractory B Cell NonHodgkins Lymphoma (GEMOX+MT3724) |
|
|
|
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (EF-24) |
III |
|
|
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields Concomitant with Gemcitabine and nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (Panova-3) |
III |
|
|
Prospective Research Assessment in Multiple Myeloma: An observational Evaluation (PREAMBLE) |
III |
|
|
Protocol for a Research Database for Hematopoietic Cell Transplantation and Cellular Therapies (CIBMTR Research Database) |
III |
|
|
Randomized Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III NonSmall Cell Lung Cancer (COAST) |
II |
|
|
Randomized Open Label Trial of Vigil in Combination with Irinotecan and Temozolomide as a Second Line Regimena for Ewing Sarcoma (CL-PTL-130) |
|
|
|
Randomized Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive, HER2 Neg, Breast Cancer (A011502) |
III |
|
|
Randomized Study of Adjuvant Concurrent Radiation and Chemotherapy vs Radiation Alone in Resected High Risk Malignant Salivary Gland Tumors (RTOG-1008) |
II |
|
|
Randomized Study of Concurrent Chemotherapy and Pelvic Radiation with or without Adjuvant Chemotherapy in High Risk Patients with Early Stage Cervical Cancer Following Radical Hysterectomy (RTOG-0724) |
III |
|
|
Randomized Study of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid (HN001) |
|
|
|
Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (16065) (UNITY205) |
II |
|
|
Randomized Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (A011401) |
III |
|
|
Randomized Trial of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High Risk Node Negative Triple Negative Invasive Breast Cancer (BR003) |
III |
|
|
Randomized Trial of Adjuvant Radiation vs Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (GOG-0263) |
III |
|
|
Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (EA3132) |
II |
|
|
Randomized Trial of Avelumab Plus Cetuximab vs Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (A091802) |
II |
|
|
Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (S1806) |
III |
|
|
Randomized Trial of Erlotinib vs Placebo in Patients with Completely Resected EGFR Mutant NonSmall Cell Lung Cancer (A081105) |
III |
|
|
Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706) |
II |
|
|
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (A021502) |
III |
|
|
Registry for Lung Screening Excellence |
|
|
|
Study Comparing Tislelizumab + Platinum And Fluoropyrimidine Versus Placebo Plus Platinum And Fluoropyrimidine As First-Line Treatment In Patients With Locally Advanced Unresectable Or Metastatic Gastric or GEJ Adenocarcinoma (BGBA317- 305) |
III |
|
|
Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202) |
II |
|
